Trademark: 87488957
Word
OXFORD BIOMEDICA
Status
Registered
Status Code
700
Status Date
Tuesday, April 24, 2018
Serial Number
87488957
Registration Number
5451207
Registration Date
Tuesday, April 24, 2018
Mark Type
4000
Filing Date
Wednesday, June 14, 2017
Published for Opposition
Tuesday, November 7, 2017

Trademark Owner History
Oxford BioMedica (UK) Limited - Original Registrant

Classifications
5 Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders
1 Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use
44 Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives
42 Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials
"OXFORD"

Trademark Events
Apr 24, 2023
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Jun 8, 2018
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 8, 2018
Teas Change Of Owner Address Received
Apr 24, 2018
Registered-Principal Register
Mar 20, 2018
1(B) Basis Deleted; Proceed To Registration
Mar 6, 2018
Notice Of Allowance Cancelled
Mar 20, 2018
Case Assigned To Intent To Use Paralegal
Mar 6, 2018
Teas Delete 1(B) Basis Received
Jan 2, 2018
Noa E-Mailed - Sou Required From Applicant
Nov 7, 2017
Official Gazette Publication Confirmation E-Mailed
Nov 7, 2017
Published For Opposition
Oct 18, 2017
Notification Of Notice Of Publication E-Mailed
Oct 1, 2017
Assigned To Lie
Sep 18, 2017
Approved For Pub - Principal Register
Sep 18, 2017
Examiner's Amendment Entered
Sep 18, 2017
Notification Of Examiners Amendment E-Mailed
Sep 18, 2017
Examiners Amendment E-Mailed
Sep 18, 2017
Examiners Amendment -Written
Sep 13, 2017
Assigned To Examiner
Jun 21, 2017
New Application Office Supplied Data Entered
Jun 17, 2017
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24